Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy.

ABSTRACT:

Background

Daptomycin-associated myopathy has been identified in 2%-14% of patients, and rhabdomyolysis is a known adverse effect. Although risk factors for daptomycin-associated myopathy are poorly defined, creatine phosphokinase (CPK) monitoring and temporary discontinuation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or "statins," has been recommended.

Methods

We conducted a single-center, retrospective, matched case-control risk factor analysis in adult and pediatric patients from 2004 to 2015. Patients in whom myopathy (defined as CPK values above the upper limit of normal) developed during daptomycin treatment were matched 1:1 to no-myopathy controls with at least the same duration of therapy. Risk factors independently associated with myopathy were

SUBMITTER: Dare RK 

PROVIDER: S-EPMC6186852 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature